FDA Panel Scheduled to Review MELA Sciences Inc.’s (MELA) MelaFind Approval Application
Medical technology company MELA Sciences Inc. recently announced that its pre-market approval (PMA) for MelaFind will undergo review by the General and Plastic Surgery Devices Panel appointed by the U.S. Food and Drug Administration (FDA) on August 26, 2010. As the deadliest form of skin cancer, melanoma is responsible for roughly 80 percent of skin cancer fatalities, and melanoma rates continue to increase with an estimated 120,000 new cases projected in 2010. There is no cure for advanced-stage melanoma, which makes early detection vital for recovery. MelaFind is the company’s hand-held imaging device that emits multiple wavelengths of light to…